MARKET

GLYC

GLYC

Glycomimetics
NASDAQ
2.290
+0.150
+7.01%
After Hours: 2.190 -0.1 -4.37% 19:58 12/02 EST
OPEN
2.130
PREV CLOSE
2.140
HIGH
2.380
LOW
2.089
VOLUME
894.53K
TURNOVER
0
52 WEEK HIGH
2.430
52 WEEK LOW
0.5100
MARKET CAP
120.05M
P/E (TTM)
-2.2218
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 2d ago
Individual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18%
If you want to know who really controls GlycoMimetics, Inc. ( NASDAQ:GLYC ), then you'll have to look at the makeup of...
Simply Wall St. · 2d ago
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?
Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Zacks · 2d ago
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Zacks · 11/23 14:55
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/21 21:32
Insider Buy: Glycomimetics
Insider Buy: Glycomimetics
MT Newswires · 11/16 16:39
InMed, AirSculpt top healthcare gainers; BrainsWay, Brookdale among losers
Seekingalpha · 11/16 15:01
Are Medical Stocks Lagging Axonics (AXNX) This Year?
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
Zacks · 11/16 14:40
More
About GLYC
GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. It has designed various small-molecule glycomimetic antagonists of galectin-3, including a product candidate that has demonstrated oral bioavailability.

Webull offers kinds of GlycoMimetics Inc stock information, including NASDAQ:GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.